Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo
Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inh...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Yamamoto-Fukuda, Tomomi [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study - Reyaz, Saima ELSEVIER, 2021, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:140 ; year:2021 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ijporl.2020.110545 |
|---|
| Katalog-ID: |
ELV052536254 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV052536254 | ||
| 003 | DE-627 | ||
| 005 | 20230624184511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijporl.2020.110545 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica |
| 035 | |a (DE-627)ELV052536254 | ||
| 035 | |a (ELSEVIER)S0165-5876(20)30688-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 004 |q VZ |
| 084 | |a 35.06 |2 bkl | ||
| 100 | 1 | |a Yamamoto-Fukuda, Tomomi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo |
| 264 | 1 | |c 2021 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model. | ||
| 650 | 7 | |a Cholesteatoma |2 Elsevier | |
| 650 | 7 | |a Level of evidence: N/A |2 Elsevier | |
| 650 | 7 | |a KGF |2 Elsevier | |
| 650 | 7 | |a p63 |2 Elsevier | |
| 650 | 7 | |a Menin-MLL inhibitor |2 Elsevier | |
| 700 | 1 | |a Akiyama, Naotaro |4 oth | |
| 700 | 1 | |a Tatsumi, Norifumi |4 oth | |
| 700 | 1 | |a Okabe, Masataka |4 oth | |
| 700 | 1 | |a Kojima, Hiromi |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Reyaz, Saima ELSEVIER |t Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study |d 2021 |g Amsterdam [u.a.] |w (DE-627)ELV006862241 |
| 773 | 1 | 8 | |g volume:140 |g year:2021 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijporl.2020.110545 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.06 |j Computeranwendungen |x Chemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 140 |j 2021 |h 0 | ||
| author_variant |
t y f tyf |
|---|---|
| matchkey_str |
yamamotofukudatomomiakiyamanaotarotatsum:2021----:eimlniiobokporsinfideaco |
| hierarchy_sort_str |
2021 |
| bklnumber |
35.06 |
| publishDate |
2021 |
| allfields |
10.1016/j.ijporl.2020.110545 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica (DE-627)ELV052536254 (ELSEVIER)S0165-5876(20)30688-1 DE-627 ger DE-627 rakwb eng 540 004 VZ 35.06 bkl Yamamoto-Fukuda, Tomomi verfasserin aut Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model. Cholesteatoma Elsevier Level of evidence: N/A Elsevier KGF Elsevier p63 Elsevier Menin-MLL inhibitor Elsevier Akiyama, Naotaro oth Tatsumi, Norifumi oth Okabe, Masataka oth Kojima, Hiromi oth Enthalten in Elsevier Science Reyaz, Saima ELSEVIER Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study 2021 Amsterdam [u.a.] (DE-627)ELV006862241 volume:140 year:2021 pages:0 https://doi.org/10.1016/j.ijporl.2020.110545 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.06 Computeranwendungen Chemie VZ AR 140 2021 0 |
| spelling |
10.1016/j.ijporl.2020.110545 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica (DE-627)ELV052536254 (ELSEVIER)S0165-5876(20)30688-1 DE-627 ger DE-627 rakwb eng 540 004 VZ 35.06 bkl Yamamoto-Fukuda, Tomomi verfasserin aut Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model. Cholesteatoma Elsevier Level of evidence: N/A Elsevier KGF Elsevier p63 Elsevier Menin-MLL inhibitor Elsevier Akiyama, Naotaro oth Tatsumi, Norifumi oth Okabe, Masataka oth Kojima, Hiromi oth Enthalten in Elsevier Science Reyaz, Saima ELSEVIER Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study 2021 Amsterdam [u.a.] (DE-627)ELV006862241 volume:140 year:2021 pages:0 https://doi.org/10.1016/j.ijporl.2020.110545 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.06 Computeranwendungen Chemie VZ AR 140 2021 0 |
| allfields_unstemmed |
10.1016/j.ijporl.2020.110545 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica (DE-627)ELV052536254 (ELSEVIER)S0165-5876(20)30688-1 DE-627 ger DE-627 rakwb eng 540 004 VZ 35.06 bkl Yamamoto-Fukuda, Tomomi verfasserin aut Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model. Cholesteatoma Elsevier Level of evidence: N/A Elsevier KGF Elsevier p63 Elsevier Menin-MLL inhibitor Elsevier Akiyama, Naotaro oth Tatsumi, Norifumi oth Okabe, Masataka oth Kojima, Hiromi oth Enthalten in Elsevier Science Reyaz, Saima ELSEVIER Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study 2021 Amsterdam [u.a.] (DE-627)ELV006862241 volume:140 year:2021 pages:0 https://doi.org/10.1016/j.ijporl.2020.110545 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.06 Computeranwendungen Chemie VZ AR 140 2021 0 |
| allfieldsGer |
10.1016/j.ijporl.2020.110545 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica (DE-627)ELV052536254 (ELSEVIER)S0165-5876(20)30688-1 DE-627 ger DE-627 rakwb eng 540 004 VZ 35.06 bkl Yamamoto-Fukuda, Tomomi verfasserin aut Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model. Cholesteatoma Elsevier Level of evidence: N/A Elsevier KGF Elsevier p63 Elsevier Menin-MLL inhibitor Elsevier Akiyama, Naotaro oth Tatsumi, Norifumi oth Okabe, Masataka oth Kojima, Hiromi oth Enthalten in Elsevier Science Reyaz, Saima ELSEVIER Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study 2021 Amsterdam [u.a.] (DE-627)ELV006862241 volume:140 year:2021 pages:0 https://doi.org/10.1016/j.ijporl.2020.110545 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.06 Computeranwendungen Chemie VZ AR 140 2021 0 |
| allfieldsSound |
10.1016/j.ijporl.2020.110545 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica (DE-627)ELV052536254 (ELSEVIER)S0165-5876(20)30688-1 DE-627 ger DE-627 rakwb eng 540 004 VZ 35.06 bkl Yamamoto-Fukuda, Tomomi verfasserin aut Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model. Cholesteatoma Elsevier Level of evidence: N/A Elsevier KGF Elsevier p63 Elsevier Menin-MLL inhibitor Elsevier Akiyama, Naotaro oth Tatsumi, Norifumi oth Okabe, Masataka oth Kojima, Hiromi oth Enthalten in Elsevier Science Reyaz, Saima ELSEVIER Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study 2021 Amsterdam [u.a.] (DE-627)ELV006862241 volume:140 year:2021 pages:0 https://doi.org/10.1016/j.ijporl.2020.110545 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 35.06 Computeranwendungen Chemie VZ AR 140 2021 0 |
| language |
English |
| source |
Enthalten in Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study Amsterdam [u.a.] volume:140 year:2021 pages:0 |
| sourceStr |
Enthalten in Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study Amsterdam [u.a.] volume:140 year:2021 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Computeranwendungen |
| institution |
findex.gbv.de |
| topic_facet |
Cholesteatoma Level of evidence: N/A KGF p63 Menin-MLL inhibitor |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study |
| authorswithroles_txt_mv |
Yamamoto-Fukuda, Tomomi @@aut@@ Akiyama, Naotaro @@oth@@ Tatsumi, Norifumi @@oth@@ Okabe, Masataka @@oth@@ Kojima, Hiromi @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV006862241 |
| dewey-sort |
3540 |
| id |
ELV052536254 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV052536254</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624184511.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijporl.2020.110545</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV052536254</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0165-5876(20)30688-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.06</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yamamoto-Fukuda, Tomomi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cholesteatoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Level of evidence: N/A</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">KGF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">p63</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Menin-MLL inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akiyama, Naotaro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tatsumi, Norifumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okabe, Masataka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kojima, Hiromi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Reyaz, Saima ELSEVIER</subfield><subfield code="t">Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study</subfield><subfield code="d">2021</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV006862241</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:140</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijporl.2020.110545</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.06</subfield><subfield code="j">Computeranwendungen</subfield><subfield code="x">Chemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">140</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Yamamoto-Fukuda, Tomomi |
| spellingShingle |
Yamamoto-Fukuda, Tomomi ddc 540 bkl 35.06 Elsevier Cholesteatoma Elsevier Level of evidence: N/A Elsevier KGF Elsevier p63 Elsevier Menin-MLL inhibitor Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo |
| authorStr |
Yamamoto-Fukuda, Tomomi |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV006862241 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences 004 - Data processing & computer science |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 004 VZ 35.06 bkl Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo Cholesteatoma Elsevier Level of evidence: N/A Elsevier KGF Elsevier p63 Elsevier Menin-MLL inhibitor Elsevier |
| topic |
ddc 540 bkl 35.06 Elsevier Cholesteatoma Elsevier Level of evidence: N/A Elsevier KGF Elsevier p63 Elsevier Menin-MLL inhibitor |
| topic_unstemmed |
ddc 540 bkl 35.06 Elsevier Cholesteatoma Elsevier Level of evidence: N/A Elsevier KGF Elsevier p63 Elsevier Menin-MLL inhibitor |
| topic_browse |
ddc 540 bkl 35.06 Elsevier Cholesteatoma Elsevier Level of evidence: N/A Elsevier KGF Elsevier p63 Elsevier Menin-MLL inhibitor |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
n a na n t nt m o mo h k hk |
| hierarchy_parent_title |
Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study |
| hierarchy_parent_id |
ELV006862241 |
| dewey-tens |
540 - Chemistry 000 - Computer science, knowledge & systems |
| hierarchy_top_title |
Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV006862241 |
| title |
Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo |
| ctrlnum |
(DE-627)ELV052536254 (ELSEVIER)S0165-5876(20)30688-1 |
| title_full |
Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo |
| author_sort |
Yamamoto-Fukuda, Tomomi |
| journal |
Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study |
| journalStr |
Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 000 - Computer science, information & general works |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Yamamoto-Fukuda, Tomomi |
| container_volume |
140 |
| class |
540 004 VZ 35.06 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Yamamoto-Fukuda, Tomomi |
| doi_str_mv |
10.1016/j.ijporl.2020.110545 |
| dewey-full |
540 004 |
| title_sort |
menin-mll inhibitor blocks progression of middle ear cholesteatoma in vivo |
| title_auth |
Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo |
| abstract |
Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model. |
| abstractGer |
Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model. |
| abstract_unstemmed |
Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo |
| url |
https://doi.org/10.1016/j.ijporl.2020.110545 |
| remote_bool |
true |
| author2 |
Akiyama, Naotaro Tatsumi, Norifumi Okabe, Masataka Kojima, Hiromi |
| author2Str |
Akiyama, Naotaro Tatsumi, Norifumi Okabe, Masataka Kojima, Hiromi |
| ppnlink |
ELV006862241 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.ijporl.2020.110545 |
| up_date |
2024-07-06T23:17:58.259Z |
| _version_ |
1803873553754357760 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV052536254</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624184511.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijporl.2020.110545</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001243.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV052536254</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0165-5876(20)30688-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.06</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yamamoto-Fukuda, Tomomi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cholesteatoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Level of evidence: N/A</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">KGF</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">p63</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Menin-MLL inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akiyama, Naotaro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tatsumi, Norifumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okabe, Masataka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kojima, Hiromi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Reyaz, Saima ELSEVIER</subfield><subfield code="t">Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study</subfield><subfield code="d">2021</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV006862241</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:140</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijporl.2020.110545</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.06</subfield><subfield code="j">Computeranwendungen</subfield><subfield code="x">Chemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">140</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.399479 |